Cargando…

The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience

Port-a-cath is a widely used device in patients with long-term venous access demand such as frequent or continuous administration of medications such as Enzyme Replacement Therapy (ERT), chemotherapy delivery, blood transfusions, blood products, and fluids. Patients with Lysosomal Storage Diseases (...

Descripción completa

Detalles Bibliográficos
Autores principales: McLoughlin, Mairead, Stepien, Karolina M., McNelly, Briony, Thompson, Lorraine, Gorton, Janet, Hendriksz, Christian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651539/
https://www.ncbi.nlm.nih.gov/pubmed/29071212
http://dx.doi.org/10.1016/j.ymgmr.2017.10.003
_version_ 1783272911043297280
author McLoughlin, Mairead
Stepien, Karolina M.
McNelly, Briony
Thompson, Lorraine
Gorton, Janet
Hendriksz, Christian J.
author_facet McLoughlin, Mairead
Stepien, Karolina M.
McNelly, Briony
Thompson, Lorraine
Gorton, Janet
Hendriksz, Christian J.
author_sort McLoughlin, Mairead
collection PubMed
description Port-a-cath is a widely used device in patients with long-term venous access demand such as frequent or continuous administration of medications such as Enzyme Replacement Therapy (ERT), chemotherapy delivery, blood transfusions, blood products, and fluids. Patients with Lysosomal Storage Diseases (LSDs) often require recurrent courses of ERT. We reviewed our experience of using port-a-caths in patients with LSDs with the focus on challenges and complications associated with these catheters. Among 245 adult patients who were treated with ERT, twenty patients (8.2%) had a port-a-cath inserted due to poor venous access. Six patients were using their first port whereas five other patients had their port-a-caths replaced at least once. The remaining six patients had inactive port-a-caths. The majority of patients with active port-a-caths never missed more than one consecutive infusion, although one patient missed 2 consecutive infusions whilst on holiday. We identified significant gaps in patients' and their families' understanding of the management of port-a-caths and risks associated with them. It resulted in producing a leaflet and designing an educational program for our LSD patients.
format Online
Article
Text
id pubmed-5651539
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-56515392017-10-25 The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience McLoughlin, Mairead Stepien, Karolina M. McNelly, Briony Thompson, Lorraine Gorton, Janet Hendriksz, Christian J. Mol Genet Metab Rep Research Paper Port-a-cath is a widely used device in patients with long-term venous access demand such as frequent or continuous administration of medications such as Enzyme Replacement Therapy (ERT), chemotherapy delivery, blood transfusions, blood products, and fluids. Patients with Lysosomal Storage Diseases (LSDs) often require recurrent courses of ERT. We reviewed our experience of using port-a-caths in patients with LSDs with the focus on challenges and complications associated with these catheters. Among 245 adult patients who were treated with ERT, twenty patients (8.2%) had a port-a-cath inserted due to poor venous access. Six patients were using their first port whereas five other patients had their port-a-caths replaced at least once. The remaining six patients had inactive port-a-caths. The majority of patients with active port-a-caths never missed more than one consecutive infusion, although one patient missed 2 consecutive infusions whilst on holiday. We identified significant gaps in patients' and their families' understanding of the management of port-a-caths and risks associated with them. It resulted in producing a leaflet and designing an educational program for our LSD patients. Elsevier 2017-10-21 /pmc/articles/PMC5651539/ /pubmed/29071212 http://dx.doi.org/10.1016/j.ymgmr.2017.10.003 Text en © 2017 Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
McLoughlin, Mairead
Stepien, Karolina M.
McNelly, Briony
Thompson, Lorraine
Gorton, Janet
Hendriksz, Christian J.
The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience
title The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience
title_full The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience
title_fullStr The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience
title_full_unstemmed The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience
title_short The use of port-a-caths in adult patients with Lysosomal Storage Disorders receiving Enzyme Replacement Therapy-one centre experience
title_sort use of port-a-caths in adult patients with lysosomal storage disorders receiving enzyme replacement therapy-one centre experience
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651539/
https://www.ncbi.nlm.nih.gov/pubmed/29071212
http://dx.doi.org/10.1016/j.ymgmr.2017.10.003
work_keys_str_mv AT mcloughlinmairead theuseofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT stepienkarolinam theuseofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT mcnellybriony theuseofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT thompsonlorraine theuseofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT gortonjanet theuseofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT hendrikszchristianj theuseofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT mcloughlinmairead useofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT stepienkarolinam useofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT mcnellybriony useofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT thompsonlorraine useofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT gortonjanet useofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience
AT hendrikszchristianj useofportacathsinadultpatientswithlysosomalstoragedisordersreceivingenzymereplacementtherapyonecentreexperience